{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:10:51Z","timestamp":1778047851772,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dispensations of opioid analgesics to patients on opioid agonist therapy (OAT) may increase the risk of overdoses. The current study\u2019s objectives are to investigate the dispensation rates and mean daily doses of dispensed opioid analgesics among patients who received OAT opioids in Norway during 2013\u20132017 and evaluate whether discontinuing OAT opioids affects the dispensed dose of opioid analgesics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Information on opioids was collected from the Norwegian Prescription Database. Dispensation rates were calculated by dividing the number of patients who were dispensed at least one opioid analgesic by the number of patients who were dispensed an OAT opioid. We calculated the mean daily dose of opioid analgesics in oral morphine equivalents. The OAT opioid dose was defined as a ratio between the dispensed doses divided by the mean recommended dose. We used logistic regression to estimate the association between the dispensation of an opioid analgesic, a dose of OAT opioids, having chronic pain, and being on palliative care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 10,371 patients were dispensed at least one OAT opioid during the study period. In 2017, 18% were dispensed an opioid analgesic with a mean daily dose of 29\u2009mg of oral morphine equivalents. Being dispensed an opioid analgesic was associated with having chronic pain (adjusted odds ratio (aOR): 3.6, 95% confidence interval: 3.2\u20134.2), being on palliative care (aOR: 6.1, 4.7\u20137.9), and receiving an OAT opioid dose below half of the recommended OAT dose (aOR: 1.7, 1.4\u20132.0). Similar results were seen in 2013\u20132016. The discontinuation of OAT opioids could increase the dose of dispensed opioid analgesics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Reducing the dispensation of opioid analgesics can be achieved by increasing the OAT opioid dose for patients on a low OAT dose, and by extending the period needed to taper off the OAT opioid dose at discontinuation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-020-05504-y","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T11:03:32Z","timestamp":1595243012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013\u20132017): a prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-7638","authenticated-orcid":false,"given":"J\u00f8rn Henrik","family":"Vold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Aas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"5504_CR1","unstructured":"Comorbidity of substance use and mental disorders in Europe. European Monitoring Centre for Drugs and Drug Addiction; 2015. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/1988\/TDXD15019ENN.pdf. Accessed Nov 2015."},{"issue":"2","key":"5504_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/pubmed\/fdx063","volume":"40","author":"E Kelty","year":"2018","unstructured":"Kelty E, Hulse G. Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls. J Public Health. 2018;40(2):409\u201314.","journal-title":"J Public Health"},{"issue":"6","key":"5504_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/JGP.0b013e31816ff35a","volume":"16","author":"D Rosen","year":"2008","unstructured":"Rosen D, Smith ML, Reynolds CF 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry. 2008;16(6):488\u201397.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"5504_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/0003-4819-144-2-200601170-00010","volume":"144","author":"DP Alford","year":"2006","unstructured":"Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127\u201334.","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"5504_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugalcdep.2011.12.007","volume":"122","author":"K van Emmerik-van Oortmerssen","year":"2012","unstructured":"van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1\u20132):11\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"5504_CR6","unstructured":"The misuse of benzodiazepines among high-risk opioid users in Europe. European Monitoring Centre for Drugs and Drug Addiction; 2018. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2733\/Misuse%20of%20benzos_POD2015.pdf. Accessed 14 Nov 2018."},{"issue":"1","key":"5504_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12888-020-02526-y","volume":"20","author":"JH Vold","year":"2020","unstructured":"Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Halmoy A, Johansson KA, Fadnes LT. Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017. BMC Psychiatry. 2020;20(1):119.","journal-title":"BMC Psychiatry"},{"issue":"1\u20133","key":"5504_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2010.12.014","volume":"116","author":"OM Fredheim","year":"2011","unstructured":"Fredheim OM, Borchgrevink PC, Nordstrand B, Clausen T, Skurtveit S. Prescription of analgesics to patients in opioid maintenance therapy: a pharmacoepidemiological study. Drug Alcohol Depend. 2011;116(1\u20133):158\u201362.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"5504_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1521-0391.2014.12091.x","volume":"23","author":"B Nosyk","year":"2014","unstructured":"Nosyk B, Fischer B, Sun H, Marsh DC, Kerr T, Rehm JT, Anis AH. High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: results from a population-level retrospective cohort study. Am J Addict. 2014;23(3):257\u201364.","journal-title":"Am J Addict"},{"issue":"50\u201351","key":"5504_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","volume":"65","author":"RA Rudd","year":"2016","unstructured":"Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(50\u201351):1445\u201352.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5504_CR11","doi-asserted-by":"publisher","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. In: Cochrane Database Syst Rev. 2014\/02\/07 edn. 2014;2:Cd002207. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"5504_CR12","doi-asserted-by":"publisher","unstructured":"Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. In: Cochrane Database Syst Rev. 2011\/08\/13 edn. 2011;8:Cd004145. https:\/\/doi.org\/10.1002\/14651858.CD004145.pub4.","DOI":"10.1002\/14651858.CD004145.pub4"},{"key":"5504_CR13","first-page":"Cd012021","volume":"9","author":"L Platt","year":"2017","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:Cd012021.","journal-title":"Cochrane Database Syst Rev"},{"key":"5504_CR14","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Bmj. 2017;357:j1550.","journal-title":"Bmj"},{"issue":"1","key":"5504_CR15","doi-asserted-by":"publisher","first-page":"e005997","DOI":"10.1136\/bmjopen-2014-005997","volume":"5","author":"HM Sun","year":"2015","unstructured":"Sun HM, Li XY, Chow EP, Li T, Xian Y, Lu YH, Tian T, Zhuang X, Zhang L. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open. 2015;5(1):e005997.","journal-title":"BMJ Open"},{"issue":"4064","key":"5504_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1126\/science.178.4064.984","volume":"178","author":"WH Oldendorf","year":"1972","unstructured":"Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 1972;178(4064):984\u20136.","journal-title":"Science"},{"key":"5504_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3389\/fpsyt.2018.00742","volume":"9","author":"F Noble","year":"2018","unstructured":"Noble F, Marie N. Management of Opioid Addiction with Opioid Substitution Treatments: beyond methadone and buprenorphine. Front Psychiatry. 2018;9:742.","journal-title":"Front Psychiatry"},{"issue":"2","key":"5504_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/204946370900300204","volume":"3","author":"V Mehta","year":"2009","unstructured":"Mehta V, Langford R. Acute Pain Management in Opioid Dependent Patients. Rev Pain. 2009;3(2):10\u20134.","journal-title":"Rev Pain"},{"issue":"3","key":"5504_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1445-5994.2012.02714.x","volume":"42","author":"B Murnion","year":"2012","unstructured":"Murnion B. Management of opioid substitution therapy during medical intervention. Intern Med J. 2012;42(3):242\u20136.","journal-title":"Intern Med J"},{"issue":"1","key":"5504_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/187447370901160321102837","volume":"9","author":"BB Dennis","year":"2016","unstructured":"Dennis BB, Bawor M, Paul J, Plater C, Pare G, Worster A, Varenbut M, Daiter J, Marsh DC, Desai D, et al. Pain and opioid addiction: a systematic review and evaluation of pain measurement in patients with opioid dependence on methadone maintenance treatment. Curr Drug Abuse Rev. 2016;9(1):49\u201360.","journal-title":"Curr Drug Abuse Rev"},{"key":"5504_CR21","first-page":"2017","volume-title":"ACTIS-RAPPORT 2","author":"ACTIS","year":"2017","unstructured":"ACTIS. Overdoses in Norway 2017: ACTIS-report 2 (overdosesituasjonen i Norge). In: ACTIS-RAPPORT 2, vol. 34; 2017. p. 2017."},{"key":"5504_CR22","volume-title":"Norwegian Centre for Addiction Research (SERAF)","author":"H Waal","year":"2017","unstructured":"Waal H, Bussesund K, Clausen T, Lillevold P, Skeie I. Statusrapport 2017, LAR 20 \u00e5r. Status, vurderinger og perspektiver. In: Norwegian Centre for Addiction Research (SERAF); 2017. https:\/\/www.med.uio.no\/klinmed\/forskning\/sentre\/seraf\/publikasjoner\/rapporter\/2018\/seraf-rapport-nr-3-2018-statusrapport-2017.pdf."},{"issue":"4","key":"5504_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1360-0443.2011.03707.x","volume":"107","author":"P Kurdyak","year":"2012","unstructured":"Kurdyak P, Gomes T, Yao Z, Mamdani MM, Hellings C, Fischer B, Rehm J, Bayoumi AM, Juurlink DN. Use of other opioids during methadone therapy: a population-based study. Addiction. 2012;107(4):776\u201380.","journal-title":"Addiction"},{"issue":"16","key":"5504_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.2017.14567","volume":"318","author":"A Kolodny","year":"2017","unstructured":"Kolodny A, Frieden TR. Ten steps the Federal Government Should Take now to reverse the opioid addiction epidemic. Jama. 2017;318(16):1537\u20138.","journal-title":"Jama"},{"key":"5504_CR25","unstructured":"Definition and general considerations. WHO Collaborating Centre for Drug Statistics; 2019. https:\/\/wwww.hoccno\/ddd\/definition_and_general_considera\/#Definition. Accessed 25 Feb 2019."},{"issue":"7","key":"5504_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269216311398300","volume":"25","author":"K Svendsen","year":"2011","unstructured":"Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25(7):725\u201332.","journal-title":"Palliat Med"},{"key":"5504_CR27","unstructured":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence In., vol. 2009. World Health Organization; 2009. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43948\/9789241547543_eng.pdf;jsessionid=6980D1DAEBFC47DF4600D3098A4BA153?sequence=1."},{"key":"5504_CR28","unstructured":"The Norwegian Prescription Database. Norwegian Institute of Public Health, Norwegian Institute of Public Health; 2019. http:\/\/www.norpd.no\/. Accessed Apr 2019."},{"key":"5504_CR29","unstructured":"The Norwegian guidelines for opioid agonist therapy. In., vol. ISBN: 978-82-8081-155-4. The Norwegian Directorate of Health; 2010. https:\/\/helsedirektoratet.no\/Lists\/Publikasjoner\/Attachments\/100\/IS-1701-Legemiddelassistert-rehabilitering-ved-opioidavhengighet.pdf. Accessed Aug 2010."},{"key":"5504_CR30","doi-asserted-by":"crossref","unstructured":"Skretting A, Rosenqvist P. Shifting focus in substitution treatment in the Nordic countries. Nordic Stud Alcohol Drugs. 2010.","DOI":"10.1177\/145507251002700604"},{"key":"5504_CR31","unstructured":"Opioid substitution therapy (Swedish: L\u00e4kemedelsassisterad behandling vid opiatberoende - Slutsatser och f\u00f6rslag). In., vol. 2015-3-35: The Swedish National Board of Health and Welfare (swedish: Socialstyrelsen); 2015."},{"key":"5504_CR32","unstructured":"Methadone and buprenorphine for the management of opioid dependence. National Institute for Health and Clinical Excellence (NICE); 2007. https:\/\/www.nice.org.uk\/guidance\/ta114\/resources\/methadone-and-buprenorphine-for-the-management-of-opioid-dependence-pdf-82598072878789. Accessed 24 Jan 2007."},{"key":"5504_CR33","unstructured":"Skurtveit S, Sakshaug S, Hjellvik V, Berg C, Handal M. Use of addictive drugs in Norway 2005-2013 (Norsk: Bruk av vanedannende legemidler i Norge 2005-2013). Norwegian Institute of Public Health; 2014. https:\/\/www.fhi.no\/globalassets\/dokumenterfiler\/rapporter\/2014\/bruk-av-vanedannende-legemidler-pdf.pdf. Accessed June 2014."},{"issue":"1\u20132","key":"5504_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pain.2006.06.009","volume":"125","author":"J Eriksen","year":"2006","unstructured":"Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1\u20132):172\u20139.","journal-title":"Pain"},{"key":"5504_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fpsyt.2018.00335","volume":"9","author":"J Delorme","year":"2018","unstructured":"Delorme J, Chenaf C, Bertin C, Riquelme M, Eschalier A, Ardid D, Authier N. Chronic pain opioid-maintained patients receive less analgesic opioid prescriptions. Front Psychiatry. 2018;9:335.","journal-title":"Front Psychiatry"},{"issue":"2","key":"5504_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5055\/jom.2007.0045","volume":"3","author":"L Manchikanti","year":"2007","unstructured":"Manchikanti L, Giordano J, Boswell MV, Fellows B, Manchukonda R, Pampati V. Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag. 2007;3(2):89\u2013100.","journal-title":"J Opioid Manag"},{"issue":"6","key":"5504_CR37","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1360-0443.2005.01074.x","volume":"100","author":"PL Brennan","year":"2005","unstructured":"Brennan PL, Schutte KK, Moos RH. Pain and use of alcohol to manage pain: prevalence and 3-year outcomes among older problem and non-problem drinkers. Addiction. 2005;100(6):777\u201386.","journal-title":"Addiction"},{"issue":"3","key":"5504_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0885-3924(00)00109-3","volume":"19","author":"SD Passik","year":"2000","unstructured":"Passik SD, Theobald DE. Managing addiction in advanced cancer patients: why bother? J Pain Symptom Manag. 2000;19(3):229\u201334.","journal-title":"J Pain Symptom Manag"},{"key":"5504_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/COPD.S15968","volume":"6","author":"MB Drummond","year":"2011","unstructured":"Drummond MB, Kirk GD, Astemborski J, McCormack MC, Marshall MM, Mehta SH, Wise RA, Merlo CA. Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. Int J Chronic Obstruct Pulmon Dis. 2011;6:89\u201395.","journal-title":"Int J Chronic Obstruct Pulmon Dis"},{"issue":"1","key":"5504_CR40","doi-asserted-by":"publisher","first-page":"e000130","DOI":"10.1136\/bmjopen-2011-000130","volume":"1","author":"I Skeie","year":"2011","unstructured":"Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H. Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study. BMJ Open. 2011;1(1):e000130.","journal-title":"BMJ Open"},{"issue":"10","key":"5504_CR41","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","volume":"26","author":"DJ Smith","year":"2015","unstructured":"Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis. Int J Drug Policy. 2015;26(10):911\u201321.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"5504_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-152-2-201001190-00006","volume":"152","author":"KM Dunn","year":"2010","unstructured":"Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85\u201392.","journal-title":"Ann Intern Med"},{"issue":"3","key":"5504_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/08897077.2015.1135225","volume":"37","author":"MC Glenn","year":"2016","unstructured":"Glenn MC, Sohler NL, Starrels JL, Maradiaga J, Jost JJ, Arnsten JH, Cunningham CO. Characteristics of methadone maintenance treatment patients prescribed opioid analgesics. Subst Abus. 2016;37(3):387\u201391.","journal-title":"Subst Abus"},{"issue":"3","key":"5504_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.pain.2004.11.011","volume":"113","author":"E Peles","year":"2005","unstructured":"Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005;113(3):340\u20136.","journal-title":"Pain"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-05504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-020-05504-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-05504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:18:02Z","timestamp":1626740282000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-020-05504-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5504"],"URL":"https:\/\/doi.org\/10.1186\/s12913-020-05504-y","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regional Committee for Medical and Health Research Ethics (REC), REC West, Norway, has approved the use of registry data for the study (reference number 2018\/939\/REK Vest, June 19, 2018). The REC committee is appointed by the Norwegian Ministry of Education and Research. No informed consent from the patients was necessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"668"}}